Alfresa Holdings Corporation
2027 Fiscal Year Q1 Financial Summary (Consolidated) [Japanese GAAP] (As of August 5, 2026)
Revenue increased 4.1% YoY to 78,896.0 million yen; operating income decreased 19.6% YoY to 5,596.0 million yen; ordinary income decreased 20.5% YoY to 6,088.0 million yen; net income attributable to owners of the parent decreased 50.5% YoY to 2,476.0 million yen. Full-year guidance unchanged, dividend forecast unchanged. Segment-wise, Medical Pharmaceuticals Wholesale: revenue 70,900.0 million yen, operating income 6,600.0 million yen; Self-Medication Wholesale: revenue 66,100.0 million yen, operating income 500.0 million yen; Manufacturing: revenue 11,900.0 million yen, operating loss 600.0 million yen; Dispensing Pharmacies: revenue 9,400.0 million yen, operating loss 400.0 million yen. New consolidation of ArkMS and investment in regenerative medicine continue. Share buyback is ongoing.
Key Figures
- Revenue: 78,896百万円（YoY +4.1％）
- Operating Income: 5,596百万円（YoY △19.6％）
- Net Income Attributable to Owners of the Parent: 2,476百万円（YoY △50.5％）
AI要約
Performance Overview
Alfresa Holdings recorded steady revenue in the first quarter of fiscal 2027, but operating income, ordinary income, and net income attributable to owners of the parent declined versus the same period a year earlier. Segment-wise, revenue remained solid in Medical Pharmaceuticals Wholesale and Self-M Medications Wholesale, though price revisions and rising logistics costs pressured profits. The company continued to add new consolidated subsidiary ArkMS and invest in regenerative medicine-related businesses to strengthen growth areas. Share buybacks are continuing as part of its capital policy.
Outlook and Investor Impact
No change to full-year guidance. Expectations show continued impact from drug price revisions and logistics costs; improving profitability will require ongoing cost management and contributions from new businesses. Strategic investments in medical devices and regenerative medicine will continue, with efforts to advance a highly efficient supply chain centered on TSCS. Expanding treasury stock holdings aims to enhance shareholder returns.
Revenue Trend
Operating Income Trend
Segment Profitability
Full-Year Guidance vs Actual
Alfresa Holdings Corporation
Company overview · Stock price · Financial data · All IR
